Premium Deze op AI gebaseerde technologische doorbraak uit de kraamkamer van Alphabet kan tot een revolutie leiden bij de ontwikkeling van nieuwe medicijnen Andrew Dunn 02 mrt 2023
Premium CRISPR pioneer Feng Zhang plans to ‘break open the barrier’ facing gene editing after raising $193 million for his secretive new startup Andrew Dunn 16 feb 2023
Premium The recipe biotech startups use to go public is being thrown out. 5 startups CEOs reveal how they’re changing their focus Andrew Dunn, Yeji Jesse Lee 26 jan 2023
Waarom techmiljardairs zoals Elon Musk, Bill Gates en Jeff Bezos investeren in startups die de hersenen met computers verbinden Andrew Dunn, Hilary Brueck 23 dec 2022
Het duurste medicijn ter wereld is net goedgekeurd, maar het kost $3,5 miljoen per behandeling: hemofiliepatiënten hebben daar gemengde gevoelens over Andrew Dunn 02 dec 2022
Premium Here are 3 ways AI is going beyond hype and transforming research at one of the world’s biggest drugmakers Andrew Dunn 22 jun 2022
EY partners are eyeing multimillion-dollar payouts from a possible split of the corporate giant’s consulting and auditing businesses Andrew Dunn 20 jun 2022
Gene-therapy biotech Bluebird Bio is set to lay off 30% of the company after warning it could struggle to survive through 2022 Andrew Dunn 05 apr 2022
Premium Big Pharma is betting billions on the next cancer breakthrough. Here are the 14 drug companies leading the way Andrew Dunn 01 apr 2022
